CHCWM – Cancer & Hematology Centers of West Michigan

KSQ-4279-1101 (KSQ Therapeutics)

Description:   A Phase 1 Study of KSQ-4279 Alone and in Combination in Patients with Advanced Solid Tumors.

Mechanism of Action: USP1 inhibitor – USP1 is a de-ubiquitinating enzyme in the DDR pathway.  USP1 inhibition leads to double stranded DNA breaks (synthetic lethality)

Target Patient Population:  Solid Tumors

Study Design:  Study drug is given orally daily.   Currently in monotherapy in dose escalation.  Phase 2 will follow with expansion in combinations with mFOLFOX, Gem/Carbo and Olaparib combinations.